President Trump's Drug Tariffs Could Impact U.S. Generic Medicine Supply
President Trump has announced a plan to impose tariffs on imported generic drugs, starting with a 100% tariff in 2028 and increasing to 200% in 2029. The policy aims to encourage domestic pharmaceutical production by making it more costly to import generics. However, experts warn that this could lead to shortages and increased costs for patients, as the U.S. heavily relies on imports for generic drugs. Currently, about 50% of generic drugs in the U.S. are manufactured in India, and 17% of active pharmaceutical ingredients come from China. The tariffs could drive foreign manufacturers out of the U.S. market, exacerbating existing drug shortages and potentially increasing reliance on more expensive branded drugs. 
